GlaxoSmithKline plc
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more
Market Cap & Net Worth: GlaxoSmithKline plc (GSKN)
GlaxoSmithKline plc (MX:GSKN) has a market capitalization of $101.30 Billion (MX$2.09 Trillion) as of March 18, 2026. Listed on the MX stock exchange, this Mexico-based company holds position #203 globally and #2 in its home market, demonstrating a 20.37% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying GlaxoSmithKline plc's stock price MX$1040.00 by its total outstanding shares 2006642158 (2.01 Billion).
GlaxoSmithKline plc Market Cap History: 2015 to 2026
GlaxoSmithKline plc's market capitalization history from 2015 to 2026. Data shows growth from $54.72 Billion to $101.30 Billion (6.41% CAGR).
GlaxoSmithKline plc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how GlaxoSmithKline plc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
2.02x
GlaxoSmithKline plc's market cap is 2.02 times its annual revenue
0.49x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
24.59x
GlaxoSmithKline plc's market cap is 24.59 times its annual earnings
10.58x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $54.72 Billion | $23.92 Billion | $8.42 Billion | 2.29x | 6.50x |
| 2016 | $68.69 Billion | $27.89 Billion | $912.00 Million | 2.46x | 75.31x |
| 2017 | $60.24 Billion | $30.19 Billion | $1.53 Billion | 2.00x | 39.32x |
| 2018 | $71.90 Billion | $30.82 Billion | $3.62 Billion | 2.33x | 19.85x |
| 2019 | $85.24 Billion | $33.75 Billion | $4.64 Billion | 2.53x | 18.35x |
| 2020 | $75.43 Billion | $34.10 Billion | $5.75 Billion | 2.21x | 13.12x |
| 2021 | $98.74 Billion | $34.11 Billion | $4.38 Billion | 2.89x | 22.52x |
| 2022 | $61.04 Billion | $29.32 Billion | $14.96 Billion | 2.08x | 4.08x |
| 2023 | $58.70 Billion | $30.33 Billion | $4.93 Billion | 1.94x | 11.91x |
| 2024 | $63.31 Billion | $31.38 Billion | $2.58 Billion | 2.02x | 24.59x |
Competitor Companies of GSKN by Market Capitalization
Companies near GlaxoSmithKline plc in the global market cap rankings as of March 18, 2026.
Key companies related to GlaxoSmithKline plc by market ranking:
- Eli Lilly and Company (NYSE:LLY): Ranked #14 globally with a market cap of $830.88 Billion USD.
- Johnson & Johnson (NYSE:JNJ): Ranked #17 globally with a market cap of $572.79 Billion USD.
- AbbVie Inc (NYSE:ABBV): Ranked #28 globally with a market cap of $387.90 Billion USD.
- AstraZeneca PLC (NASDAQ:AZN): Ranked #45 globally with a market cap of $295.24 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #14 | Eli Lilly and Company | NYSE:LLY | $830.88 Billion | $930.35 |
| #17 | Johnson & Johnson | NYSE:JNJ | $572.79 Billion | $238.11 |
| #28 | AbbVie Inc | NYSE:ABBV | $387.90 Billion | $219.76 |
| #45 | AstraZeneca PLC | NASDAQ:AZN | $295.24 Billion | $191.29 |
GlaxoSmithKline plc Historical Marketcap From 2015 to 2026
Between 2015 and today, GlaxoSmithKline plc's market cap moved from $54.72 Billion to $ 101.30 Billion, with a yearly change of 6.41%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | MX$101.30 Billion | +20.37% |
| 2025 | MX$84.16 Billion | +32.92% |
| 2024 | MX$63.31 Billion | +7.85% |
| 2023 | MX$58.70 Billion | -3.82% |
| 2022 | MX$61.04 Billion | -38.18% |
| 2021 | MX$98.74 Billion | +30.90% |
| 2020 | MX$75.43 Billion | -11.51% |
| 2019 | MX$85.24 Billion | +18.55% |
| 2018 | MX$71.90 Billion | +19.37% |
| 2017 | MX$60.24 Billion | -12.30% |
| 2016 | MX$68.69 Billion | +25.53% |
| 2015 | MX$54.72 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of GlaxoSmithKline plc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $101.30 Billion USD |
| MoneyControl | $101.30 Billion USD |
| MarketWatch | $101.30 Billion USD |
| marketcap.company | $101.30 Billion USD |
| Reuters | $101.30 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.